Maintenance treatment for advanced ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study tests a new maintenance therapy for people with advanced ovarian cancer that has responded well to initial chemotherapy. The goal is to see if it helps keep the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have been diagnosed with stage III or IV ovarian, fallopian tube, or primary peritoneal cancer.
- You have completed at least one line of platinum-based chemotherapy and your cancer has responded (shrinkage or stable).
- Your tumor does not have certain genetic changes (BRCA mutation or homologous repair deficiency).
- You have not previously taken PARP inhibitors for maintenance.
- You are willing to provide a tumor sample for testing if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called mocertatug rezetecan combined with bevacizumab against standard platinum chemo plus bevacizumab. It's for women with ovarian cancer that came back after treatment and is still sensitive to platinum drugs.
This phase 3 trial tests a new drug, mocertatug rezetecan, against standard treatments for ovarian cancer that no longer responds to platinum chemo. It's for people who have had 1 to 4 prior therapies and may offer a new option if you haven't tried all standard treatments yet.
This trial tests a new drug combination (torvutatug samrotecan plus bevacizumab) as maintenance therapy to help keep advanced ovarian cancer from growing after initial chemotherapy. It is for people whose tumors do not have a specific genetic change called HRD.
This trial tests a new drug called torvutatug samrotecan, alone or with bevacizumab, as a maintenance therapy after chemotherapy for ovarian cancer that has come back. It aims to help keep the cancer from growing for a longer time.
This study tests a new maintenance therapy (mocertatug rezetecan) to help keep endometrial cancer from coming back after initial chemotherapy and immunotherapy. It may help people whose cancer had a good response to first-line treatment.
This study tests a new maintenance treatment (sacituzumab tirumotecan) versus standard care for people with ovarian cancer that has come back after responding to platinum-based chemotherapy. The goal is to see if it can keep the cancer from growing longer and improve quality of life.
Hear when a new Ovarian Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.